Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.60
-0.45 (-4.97%)
At close: Nov 21, 2025, 4:00 PM EST
8.79
+0.19 (2.21%)
After-hours: Nov 21, 2025, 7:12 PM EST
Zevra Therapeutics Employees
Zevra Therapeutics had 59 employees as of December 31, 2024. The number of employees decreased by 10 or -14.49% compared to the previous year.
Employees
59
Change (1Y)
-10
Growth (1Y)
-14.49%
Revenue / Employee
$1,430,305
Profits / Employee
$508,746
Market Cap
484.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59 | -10 | -14.49% |
| Dec 31, 2023 | 69 | 33 | 91.67% |
| Dec 31, 2022 | 36 | 12 | 50.00% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZVRA News
- 2 days ago - Zevra Therapeutics, Inc. Announces CFO Transition - GlobeNewsWire
- 17 days ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Zevra Reports Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 24 days ago - Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 26 days ago - Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire